TAAR1 agonists for the treatment of stimulant use disorder

Active Grant Awarded

Award ID
R43DA061847
Recipient
Awarding agency
Obligated
$398,947

Award facts

Assistance listing
93.279 Drug Use and Addiction Research Programs
Completion date 46% complete
Place of performance
Paramus, NJ 07652, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services, National Institutes of Health, through the National Institute on Drug Abuse, awarded Psychogenics Inc. a grant totaling $398,947 on June 9, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279). The award funds preclinical evaluation of two molecules with different mechanisms of action as potential treatments for cocaine use disorder, for which the source notes no approved medications exist. The recipient will test whether each compound reduces cocaine infusions under a fixed ratio self-administration schedule and compare that effect with non-drug reinforcement. The most effective molecule will then be assessed in a stress-induced reinstatement assay that measures prevention of relapse after a drug-free period. If a single dose proves effective, the study will examine repeated administration. The work will also determine whether the compound alters the reinforcing value of food. The resulting data will show whether the compound's effects are selective for drug or non-drug reinforcers. Obligated funding equals the award total of $398,947, the period of performance ends May 31, 2027, and work is performed in Paramus, New Jersey 07652.

Description

Abstract
Cocaine use disorder (CUD) is a serious public health concern in the united states. Approximately 0.5% of the US population have CUD, and these people are more prone to death, particularly by overdose, suicide, and cardiovascular events. CUD treatment focuses on psychological therapies, which are expensive and only moderately effective. There are no approved medications for CUD, thus identifying novel pharmacotherapies for this disorder is an important unmet need. The long-term goal of this project is to bring to market a safe and effective pharmaceutical drug treatment that leverages novel mechanisms of action to reduce cocaine use and improve abstinence. We have discovered two molecules featuring different mechanisms of action that may plausibly be effective in treating CUD. The current project will evaluate these two compounds for their effects in behavioral models evaluating cocaine- and non-drug-related reinforcement, and stress-induced reinstatement of drug-seeking behavior. Specifically, we will evaluate the ability of these two molecules to reduce the number of cocaine infusions in cocaine self-administration studies based on a fixed ratio schedule of reinforcement. We will then evaluate the most effective molecule in a stress-induced reinstatement assay, which evaluates the ability of the compound to prevent a relapse induced by stress after a drug-free period. If our compound is effective with a single dose, we will examine whether IT remains effective at suppressing stress-induced reinstatement after repeated administration. Finally, we will evaluate whether the effects of the compound also modify the reinforcing value of food in a fixed ratio schedule of reinforcement. The resulting data will help US understand to what extent the effects of the compound are selective for drug and non-drug reinforcers.

Quick answers

Who received award R43DA061847?

R43DA061847 was awarded to Psychogenics Inc. by National Institute on Drug Abuse (National Institutes of Health) on June 9, 2026.

How much is award R43DA061847 worth?

$398,947 has been obligated on R43DA061847.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award